Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population
Launched by HARVARD SCHOOL OF PUBLIC HEALTH (HSPH) · Jun 19, 2017
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
Emerging evidence has shown that peanut consumption has beneficial effects in modifying lipid profiles, glucose, and other cardiometabolic risk factors. During the last two decades, China has experienced a dramatic increase in T2D prevalence largely due to rapid social and economic growth. Peanuts are commonly consumed as snacks in China. However, there is limited evidence on the specific health benefits of peanuts as part of the Chinese habitual diet.
Clinical Study Protocol
Study diet Subjects will consume their habitual diet with the test snacks provided as roasted peanuts and rice flo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20-65
- • Increased waist circumference : ≥ 90 cm for men and ≥ 80 cm for women
- Plus 1 or more of the remaining criteria:
- • Elevated TG level ≥ 1.7 mmo/L
- • Reduced HDL-Cholesterol \< 1.03 mmol/L in men and \< 1.29 mmol/L in women)
- • Fasting glucose ≥ 5.6 mmol/L
- • Systolic/diastolic blood pressure ≥ 130/85 mmHg.
- Exclusion Criteria:
- • Taking lipid lowering medications
- • With known or unknown peanut allergy (or any peanut containing products)
- • Thyroid disease
- • Diabetes mellitus
- • Kidney disease
- • Liver disease
- • Cardiovascular disease or cancer
- • Pregnant or lactating women
- • Heavy alcohol consumption (\>14 drinks/week)
About Harvard School Of Public Health (Hsph)
The Harvard School of Public Health (HSPH), now part of Harvard T.H. Chan School of Public Health, is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and innovative research initiatives, HSPH focuses on addressing pressing global health challenges through multidisciplinary approaches. The institution actively sponsors clinical trials aimed at improving health outcomes, informing public policy, and enhancing community well-being. With a commitment to scientific excellence and social responsibility, HSPH collaborates with various stakeholders to translate research findings into practical solutions that benefit populations worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Xiaoran Liu, PhD
Principal Investigator
Harvard School of Public Health (HSPH)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials